Article Information
PubMed
History
- Published online October 27, 2003.
Copyright & Usage
© 2003 Canadian Medical Association or its licensors
Author Information
- Jacques Genest,
- Jiri Frohlich,
- George Fodor,
- Ruth McPherson
- Dr. Genest is with the Royal Victoria Hospital, McGill University, Montréal, Que. Dr. Frohlich is with St. Paul's Hospital, University of British Columbia, Vancouver, BC. Drs. Fodor and McPherson are with the University of Ottawa Heart Institute, Ottawa, Ont.
- Correspondence to:
Dr. Jacques Genest, Division of Cardiology, McGill University Health Centre, Royal Victoria Hospital, 687 Pine Ave. W, Montréal QC H3A 1A1; fax 514 843-2813; jacques.genestmuhc.mcgill.ca
Cited By...
In this issue
Article tools
Respond to this article
Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update
Jump to section
Related Articles
Cited By...
- Double-blind randomised controlled trial of the independent and synergistic effect of Spirulina maxima with exercise (ISESE) on general fitness, lipid profile and redox status in overweight and obese subjects: study protocol
- Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review
- Quality of Care for First Nations and Non-First Nations People with Diabetes
- Association of Apolipoprotein B and Nuclear Magnetic Resonance Spectroscopy-Derived LDL Particle Number with Outcomes in 25 Clinical Studies: Assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices
- Inclusion of Stroke in Cardiovascular Risk Prediction Instruments: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
- Comprehensive Cardiac Rehabilitation for Secondary Prevention After Transient Ischemic Attack or Mild Stroke: I: Feasibility and Risk Factors
- A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study
- Cost Effectiveness and Screening Interval of Lipid Screening in Hodgkin's Lymphoma Survivors
- Lipid Treatment Assessment Project 2: A Multinational Survey to Evaluate the Proportion of Patients Achieving Low-Density Lipoprotein Cholesterol Goals
- Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
- Re-Evaluating Therapeutic Target Goals for Statin-Treated Patients: Time for Revolutionary Changes?
- Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease
- Appropriateness of current thresholds for obesity-related measures among Aboriginal people
- One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk
- Are patients with hyperlipidemia undertreated?: Study of patients admitted to hospital with coronary events
- Do Women Have Worse Outcome After Stroke Caused by Intracranial Arterial Stenosis?
- Lignes directrices canadiennes de 2006 sur la prise en charge et la prevention de l'obesite chez les adultes et les enfants [sommaire]
- 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]
- A comprehensive view of sex-specific issues related to cardiovascular disease
- The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin
- Risk Equation Determining Unsuccessful Cannulation Events and Failure to Maturation in Arteriovenous Fistulas (REDUCE FTM I)
- Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: modelling study
- Effect of Ezetimibe on the In Vivo Kinetics of ApoB-48 and ApoB-100 in Men With Primary Hypercholesterolemia
- Revisiting Rose: strategies for reducing coronary heart disease
- An evaluation of class effect
- Questioning the benefits of statins
- Questioning the benefits of statins
- Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Heterozygous Familial Hypercholesterolemia
- Screening for Dysbetalipoproteinemia by Plasma Cholesterol and Apolipoprotein B Concentrations
- The analysis by Manuel and colleagues creates controversy with headlines, not data
- The 2003 Canadian recommendations for dyslipidemia management: Revisions are needed
- Rebuttal
- Comparison of the Associations of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in Patients With the Metabolic Syndrome in the Insulin Resistance Atherosclerosis Study
- Dyslipidemia guidelines
- Dyslipidemia guidelines
- Dyslipidemia guidelines
More in this TOC Section
Similar Articles
